Notably, inhibition of the phosphatidylinositol 3-kinase/Akt pathway by the inhibitor, LY294002, failed to inhibit Ser186 phosphorylation, consistent with phosphorylation of this residue by a protein kinase(s) that is independent of the phosphatidylinositol 3-kinase pathway

Notably, inhibition of the phosphatidylinositol 3-kinase/Akt pathway by the inhibitor, LY294002, failed to inhibit Ser186 phosphorylation, consistent with phosphorylation of this residue by a protein kinase(s) that is independent of the phosphatidylinositol 3-kinase pathway. pathological levels, behaves as a classic dominant oncogene that stimulates a protective response through induction of the p53 pathway. The p53 tumor suppressor is Tariquidar (XR9576) a potent transcription factor that promotes the arrest or elimination of hyperproliferative or genotoxically damaged cells (reviewed in Refs. 1 and 2). Under normal circumstances, Mdm2, an E32 ubiquitin ligase, mediates ubiquitylation and proteasome-dependent Tariquidar (XR9576) degradation of p53 (3). Cellular stresses that induce p53 target the p53-Mdm2 interaction with the effect of attenuating p53 degradation (4). is overexpressed or amplified in a range of human tumors that retain wild type p53 with the outcome that p53 levels are thought to be suppressed (3). Mdm2 plays a pivotal role in integrating signals coming into the p53 pathway. For example, the Mdm2 inhibitor, ARF, is induced by hyperproliferative signals, leading to inhibition of p53 and Mdm2 degradation (5-9) and, consequently, the elimination of cells with tumorigenic potential (10). Mdm2 is also regulated by a series of phosphorylation and dephosphorylation events, mainly, but not exclusively, in response to DNA damage (reviewed in Ref. 11). Among these, serine residues 166 and 186 were identified as targets of the Akt protein kinase and shown to be modified in established cell lines in response to serum and to individual survival factors (12-18). Interaction with and phosphorylation by Akt was variously reported to lead to nuclear localization of Mdm2, increased ubiquitylation of p53, increased degradation of p53, decreased association with ARF, and increased interaction with p300 (12-18), events consistent with lowering p53 levels and increasing the threshold required to initiate arrest or apoptosis. Recently, however, this Tariquidar (XR9576) paradigm has been challenged in a mouse model for prostate cancer, where loss of PTEN, which promotes constitutive activation of Akt, leads to induction of the p53 pathway and, consequently, cellular senescence (19). The Pim proteins (Pim-1, Pim-2, and Pim-3 (also known as KID-1)) are a family of short lived protein serine/threonine kinases that are expressed at low levels physiologically, mainly in hematopoietic cells, and Tariquidar (XR9576) are transiently induced in response to a host of cytokines (reviewed in Refs. 20 and 21). Mice lacking expression of all three Pim kinases develop normally but are smaller than their wild type counterparts and have impaired responses to certain hematopoietic growth factors (22). Pim and Akt kinases have overlapping but independent regulatory roles in hematopoietic cells (23) and share a growing number of common substrates. Among these, Mdm2 was shown to be phosphorylated by Pim-1 (24). However, neither the site(s) of phosphorylation nor the effects of Pim-1 on Mdm2 function were established. From a pathological perspective, elevated expression of Pim kinases has been implicated in tumor development and particularly in lymphomagenesis (assessed in Refs. 21, 25, and 26). For example, the and genes were originally identified as common proviral integration sites in Moloney murine leukemia virus-induced lymphomas (25). Expression of or in transgenic mice (27, 28). Pim kinases are significantly overexpressed in various human cancers, including prostate cancer (29), lymphoma (30), leukemia (31), multiple myeloma (32), pancreatic cancer (33), and colon cancer (34), suggesting a contributory role in human pathogenesis. The percentage of human hematological malignancies showing p53 Rabbit Polyclonal to Tubulin beta mutation is low (15% as compared with 50% in tumors of the esophagus, ovary, and colorectum (International Agency for Research on Cancer data base)), suggesting that mechanisms other than p53 mutation (such as ARF loss or amplification) are likely to be Tariquidar (XR9576) significant in promoting dysfunction of the p53 pathway in these tumors. Pim-1 can associate with Mdm2 (24), suggesting the possibility that elevated expression of oncogenes such as might.